Pharmaids Pharmaceuticals Limited (BOM:524572)

Market Cap	1.07B -47.5%
Revenue (ttm)	253.40M +18.5%
Net Income	-45.60M
EPS	-2.29
Shares Out	35.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	482
Open	30.00
Previous Close	30.15
Day's Range	29.60 - 30.50
52-Week Range	25.60 - 60.00
Beta	-0.11
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Pharmaids Pharmaceuticals

Pharmaids Pharmaceuticals Limited, together with its subsidiaries, provides contract research and manufacturing services for pharma, biotech, agro, and chemical industries in India. It provides pharma intermediates, such as Dichloro Benzoyl nitrile, hydrazine carboximidamide 2 methane, pyridine carbonitrile, pyridine carboxylic acid, 8-chloro-10, 11-dihydro-4-aza-5H-dibenzo cycloheptene-5-one, 8-chloro-6,11-dihydro-11 cyclohepta pyridine, 2-amino-5-methylthiopene-3-carbonitrile, 5-methyl-2-amino thiophene-3-carbonitrile, 4-amino-2-methyl-10h-th...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 127
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524572

Financial Performance

In fiscal year 2026, Pharmaids Pharmaceuticals's revenue was 278.82 million, an increase of 43.37% compared to the previous year's 194.47 million. Losses were -117.17 million, 8.73% more than in 2025.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 7, 2026

Data Sources Report a data error